DEKA
31.1.2024 16:01:35 CET | Business Wire | Press release
DEKA, an Italian subsidiary of the El.En. Group, listed on the Eurostar Next of Borsa Italiana (ELN.MI), specialized in the development and production of pioneering Energy Based devices for aesthetics and surgery, on the occasion of the 25th IMCAS World Congress, which will be held in Paris from February 1-3, has announced the launch of 4 new laser platforms which integrate the “PRO” line, presented during the World Congress of Dermatology (WCD) held in Singapore last July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131482600/en/
(Photo: DEKA)
After the success obtained in the US and Canada, DEKA, with its laser systems, among which the very famous lunch-time CoolPeel® treatment for face rejuvenation, and epilation is now introducing the TETRA PROTM, MOTUS PROTM, SMARTXIDE PROTM and TOROTM platforms to the market.
With these new solutions DEKA transforms traditional dermatology laser technology paradigms, aesthetic medicine and dermatologic surgery, opening them to new practical frontiers.
Riccardo Stocchi – The company’s Innovation Manager stated: “The enthusiasm for the success we obtained with the PRO line and the ability to anticipate physicians’ requests, have turned, once again, into DEKA’s ability to create innovation, paying close attention to product positioning and correct segmentation of the reference market, responding with breakthrough technologies, which provide enormous benefits to both operators and patients. The road marked by DEKA, which has invested substantially in research and development and clinical research, obtaining extraordinary results, highlights, besides high efficacy and safety standards, maniacal attention to detail, from equipment design to software usability, with more and more innovative graphic user interfaces, which are absolutely intuitive and user friendly".
Paolo Salvadeo, DEKA’s CEO and El.En.’s General Manager, echoes Mr. Stocchi by adding: "These four new laser solutions, which see the light after few months from the launch of the PRO line, are the umpteenth demonstration of the efficacy of our organizational and R&D model. The path is marked. Thanks to DEKA’s strong aid, our group, in the medical segment, not only wishes to assert itself as the first player in the medical laser segment worldwide, but also to prospectively maintain a strong leadership position with regard to the market and competition. It is a fast-running machine, which we have no intention of slowing down".
Talking specifically about the four DEKA novelties, TETRA PROTM carries on the success seen by the birth of the “CoolPeel®” treatment/phenomenon in the US. TETRA PROTM, with its 40W of power, is the evolution of the 30W “SmartXide Tetra” CO2 laser, with a broader scanning area and treatment time reduction by 25%. The new “TETRA MOVEO” scanning mode also allows for treatment time reduction of the Made in the USA “CoolPeel®”. The ability to execute different treatments, from traditional and fractional rejuvenation, to various types of scar tissue, also deep, ultrafast vaporisations and other treatments which fall within various disciplines, completes the versatility of this new technology.
MOTUS PROTM is the latest evolution of the Motus line, Alexandrite laser and Nd:YAG, which has revolutionized the paradigms of epilation thanks to its high efficacy and very high comfort for the patient, also opening itself up to vascular treatments, up to the latest Made in the USA “MOVEO GLO”, which offers a complete face treatment, in the same session, to achieve optimal results at pigmentary, vascular and chrono-photo aging level. The “3 in 1” treatment with “GLO(W)” effect.
New design, more peak power, handled by a new software and mitigated by a new cooling system to carry forward the worldwide success in epilation signed by DEKA, are only a few of the novelties of the MOTUS PROTM technology.
Going back to CO2 Laser technology, SmartXide PROTM replicates the success of its predecessor, SmartXide DOT, the first fractional laser on the market, which has obtained success the world over, in particular in the United States, also known for periocular and blepharoplasty treatments.
Another important novelty is TOROTM, the laser device that the market had long been waiting for to act on more fronts: Spots, tattoos, rejuvenation, ranging from scar tissue to toning, all the way to the DEKAPeel treatment, to quickly intervene on dilated pores and obtain general improvement of cutaneous texture.
2 wavelengths, 1064 and 532 nm Q-Switched, and a third, 785nm, operating in the picosecond range, guarantee treatment efficacy and safety. TOROTM has been engineered especially for those skin types, among which Asian ones, which may benefit from this ultrafast coherent radiation, in terms of treatment efficacy and safety. By means of a pre-set database, which offers several clinical cases and a guided path throughout the various parameters which involve several targets (spot depth, tattoo color, typology of benign pigmented lesions, rejuvenation type and toning), TOROTM guides the physician, whilst guaranteeing treatment efficacy and safety.
Information on DEKA M.E.L.A.
DEKA M.E.L.A. is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.
This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients, and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.
DEKA means reaching perfection and excellence and it is “10”, the perfect number according to the philosopher and mathematician Pythagoras.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131482600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release
Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release
India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing
Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 10:16:00 CET | Press release
In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
